Medically reviewed by Dr. Golsa Gholampour, MD. Last updated April 2026.

Key Takeaways

  • GLP-1 medications carry an FDA boxed warning about thyroid C-cell tumors, but this finding comes from animal studies using doses far higher than what humans receive.
  • No confirmed link has been established in humans between GLP-1 medications and thyroid cancer in humans.
  • People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not take GLP-1 medications.
  • Common thyroid conditions like hypothyroidism and Hashimoto's disease are usually not reasons to avoid these medications.
  • Your provider will likely check thyroid function with a TSH blood test before starting treatment.
  • Always disclose your full thyroid history to your prescribing provider.

Understanding the Boxed Warning

If you have read the prescribing information for any GLP-1 medication, whether semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), or liraglutide (Saxenda), you have seen the boxed warning. It is the most prominent safety alert the FDA can require, printed inside a black border at the top of the label.

The warning states that GLP-1 receptor agonists caused thyroid C-cell tumors, including medullary thyroid carcinoma, in rodents. It advises against use in patients with a personal or family history of MTC or in patients with MEN2.

This may sound concerning. But the context matters, and understanding the science behind this warning is important for making an informed decision with your provider.

For a broader overview of GLP-1 safety considerations, see our safety guide.

What the Animal Studies Actually Found

The thyroid C-cell tumor finding comes from studies in rats and mice. In these studies, rodents were given GLP-1 receptor agonists at doses significantly higher than what is prescribed to humans, and for durations that represent a much larger proportion of the animal's lifespan.

Why Rodent Results May Not Apply to Humans

Rats and humans have very different thyroid biology. Specifically:

  • Rodent thyroid C-cells have a high density of GLP-1 receptors. When these receptors are stimulated for extended periods at high doses, C-cells can increase in number and may form tumors.
  • Human thyroid C-cells have far fewer GLP-1 receptors. Multiple studies examining human thyroid tissue have found very low or minimal GLP-1 receptor presence on C-cells, which suggests the mechanism that drives tumors in rodents may not be relevant in humans.
  • The doses used in animal studies were many times higher than the therapeutic doses used in human patients, adjusted for body weight.

This difference is important to understand. The FDA requires the boxed warning based on the animal data, but it does not mean the risk has been confirmed in people.

What Human Data Shows

Since GLP-1 medications have been on the market for over 15 years (liraglutide was approved in 2010), researchers have had more than a decade of real-world data.

Large-Scale Safety Studies

Several large studies and meta-analyses have examined the relationship between GLP-1 medications and thyroid cancer in human populations:

  • A 2023 meta-analysis published in Diabetes Care examining data from multiple randomized controlled trials found no statistically significant increase in thyroid cancer among GLP-1 users compared to placebo groups.
  • Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) has not identified a clear signal of increased MTC risk.
  • The SUSTAIN and STEP clinical trial programs for semaglutide, which enrolled thousands of participants, did not show an increased rate of thyroid malignancies.

However, some observational studies have suggested a small and uncertain signal that warrants continued monitoring. The medical community has not reached consensus on whether this represents a true risk or a statistical artifact.

Calcitonin Monitoring

Calcitonin is a hormone produced by thyroid C-cells and serves as a marker for MTC. Early in the development of GLP-1 drugs, researchers monitored calcitonin levels in trial participants. The results consistently showed no meaningful increase in calcitonin levels in humans taking GLP-1 medications at standard doses.

Who Should Definitely Not Take GLP-1 Medications

The contraindications are specific and clear:

Medullary Thyroid Carcinoma (MTC)

If you have been diagnosed with MTC, or if you have a first-degree relative (parent, sibling, or child) who has been diagnosed with MTC, GLP-1 medications are contraindicated. This is a clear contraindication.

MTC is rare, accounting for about 3% to 5% of all thyroid cancers. But because the animal studies showed GLP-1 receptor stimulation can promote this specific type of thyroid cancer in rodents, the precautionary principle applies.

Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2)

MEN2 is a genetic condition that dramatically increases the risk of developing MTC. If you have MEN2 or are known to carry the RET gene mutation associated with it, GLP-1 medications are not appropriate for you. Your endocrinologist can test for this if there is any suspicion based on your family history.

Common Thyroid Conditions That Are Generally Safe

Many people have thyroid conditions that are unrelated to C-cell tumors. In most cases, these do not prevent you from using GLP-1 medications.

Hypothyroidism

Having an underactive thyroid, whether due to Hashimoto's disease, surgical removal, or radioactive iodine treatment, is not considered a reason to avoid GLP-1 therapy. Hypothyroidism is one of the most common endocrine conditions, affecting roughly 5% of the U.S. adult population. If your thyroid levels are well-managed with levothyroxine or a similar medication, GLP-1 treatment is generally considered safe when appropriately managed.

Hashimoto's Thyroiditis

This autoimmune condition is the most common cause of hypothyroidism. It affects the thyroid's ability to produce hormones but involves the follicular cells, not the C-cells. Since GLP-1 concerns relate specifically to C-cells, Hashimoto's is not a contraindication.

Graves' Disease

Graves' disease causes hyperthyroidism and, like Hashimoto's, involves follicular cells and autoimmune processes unrelated to C-cell biology. It is generally not considered a contraindication, though your provider may want your thyroid levels stabilized before starting GLP-1 therapy.

Thyroid Nodules

Benign thyroid nodules are extremely common and usually unrelated to MTC. However, if you have nodules that have not been evaluated, your provider may want to order an ultrasound or fine-needle aspiration before starting treatment to rule out cancer.

Previous Papillary or Follicular Thyroid Cancer

These are the most common types of thyroid cancer and arise from follicular cells, not C-cells. A history of papillary or follicular thyroid cancer is not the same as a history of MTC. Many providers are comfortable prescribing GLP-1 medications to patients with a history of these cancers, though this is a case-by-case decision.

What to Discuss With Your Doctor

Before starting GLP-1 therapy, have a thorough conversation about your thyroid history. Specifically:

  • Disclose any personal or family history of thyroid cancer, including the specific type if known.
  • Mention any thyroid nodules, even if they have been previously evaluated.
  • Share your current thyroid medication regimen and most recent lab results.
  • Ask about baseline thyroid function testing, including TSH and potentially calcitonin if you have risk factors.
  • Discuss ongoing monitoring and what symptoms to watch for during treatment.

Your provider should check thyroid function before prescribing and may include periodic monitoring as part of your treatment plan. For more about GLP-1 side effects and what to watch for, see our side effects guide.

Symptoms to Report During Treatment

While on GLP-1 medication, report any of the following to your provider promptly:

  • A new lump or swelling in your neck
  • Difficulty swallowing or a sensation of pressure in your throat
  • Hoarseness that does not go away
  • Shortness of breath unrelated to other causes

These symptoms do not necessarily indicate thyroid cancer, but they should be evaluated by your provider. Learn more about all GLP-1 medications and their safety profiles on our medications page.

The Bottom Line

For the vast majority of patients, including those with common thyroid conditions like hypothyroidism and Hashimoto's, GLP-1 medications are generally considered safe. The boxed warning exists because of animal study findings that have not been replicated in humans. However, the contraindication for MTC and MEN2 is a clear contraindication and should be followed.

If you have any thyroid history, the right approach is transparency with your provider and appropriate baseline testing before starting treatment.

Sources

  1. FDA Prescribing Information for Wegovy (semaglutide injection). Revised 2024.
  2. Bjerre Knudsen L, et al. "Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation." Endocrinology. 2010;151(4):1473-1486.
  3. Hegedus L, et al. "GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects." Journal of Clinical Endocrinology & Metabolism. 2011;96(3):853-860.
  4. Bezin J, et al. "GLP-1 Receptor Agonists and the Risk of Thyroid Cancer." Diabetes Care. 2023;46(2):384-390.
  5. American Thyroid Association. "Medullary Thyroid Cancer." Thyroid.org. 2024.